Wang J, Macoritto M, Guay H, Davis JW, et al. The Clinical Response of Upadacitinib and Risankizumab Is Associated With Reduced Inflammatory Bowel Disease Anti-TNF-alpha Inadequate Response Mechanisms. Inflamm Bowel Dis 2022 Dec 14:izac246. doi: 10.1093.
PMID: 36515243